LON:EDEN Eden Research (EDEN) Share Price, News & Analysis GBX 2.98 -0.02 (-0.70%) As of 07:12 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Eden Research Stock (LON:EDEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eden Research alerts:Sign Up Key Stats Today's Range 2.98▼ 350-Day Range 2.92▼ 3.9752-Week Range 2.23▼ 4.60Volume116,305 shsAverage Volume484,128 shsMarket Capitalization£15.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: Based on plant-derived active ingredients, Mevalone ® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally. Cedroz ™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally. Eden's Sustaine ® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. For more information about Eden, please visit: www.edenresearch.com . Read More Receive EDEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eden Research and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDEN Stock News HeadlinesOle Miss research shows promise for breast cancer treatmentSeptember 9, 2025 | msn.com“Eden ”ending explained: Ron Howard breaks down the real-life murder mysteryAugust 24, 2025 | msn.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 16 at 2:00 AM | Paradigm Press (Ad)Ron Howard on assembling a star-studded cast for thriller 'Eden'August 22, 2025 | msn.comHere’s why Texas is one of the most dangerous states to raise a family in 2025July 16, 2025 | msn.comYgia acquires Eden to become Cyprus’ largest private hospital groupJuly 15, 2025 | msn.comEden Research partners with Royal Holloway on seed treatment productJune 16, 2025 | lse.co.ukEden Expands Metabolic Health Access Services with NAD⁺ via Injections, Patch, and Nasal-Spray FormatsMay 29, 2025 | finance.yahoo.comSee More Headlines EDEN Stock Analysis - Frequently Asked Questions How have EDEN shares performed this year? Eden Research's stock was trading at GBX 3.90 on January 1st, 2025. Since then, EDEN shares have decreased by 23.6% and is now trading at GBX 2.98. How were Eden Research's earnings last quarter? Eden Research plc (LON:EDEN) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.36) EPS for the quarter. Eden Research had a negative net margin of 38.70% and a negative trailing twelve-month return on equity of 11.63%. How do I buy shares of Eden Research? Shares of EDEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Eden Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eden Research investors own include Kromek Group (KMK), Primary Health Properties (PHP), National Grid (NG.L), Cabot Energy (CAB), EPE Special Opportunities (ESO), Marston's (MARS) and Mothercare (MTC). Company Calendar Last Earnings5/06/2025Today9/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Agricultural Inputs Sub-IndustryN/A Current SymbolLON:EDEN CIKN/A Webwww.edenresearch.com Phone+44-1285-359555FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 0 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-38.70% Pretax MarginN/A Return on Equity-11.63% Return on Assets-11.29% Debt Debt-to-Equity Ratio1.26 Current Ratio3.80 Quick Ratio2.42 Sales & Book Value Annual Sales£4.30 million Price / Sales3.72 Cash FlowGBX 0.25 per share Price / Cash Flow11.90 Book ValueGBX 2.38 per share Price / Book1.26Miscellaneous Outstanding Shares533,353,000Free FloatN/AMarket Cap£16.00 million OptionableNot Optionable Beta0.92 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (LON:EDEN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eden Research plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Eden Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.